Results for this period
First quarter2025年4月1日〜2025年6月30日ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
国内では採卵針・カテーテルの新製品・改良品の販売が好調。海外では欧州の新製品展開・新規顧客開拓、インドの顧客開拓が進展した一方、タイ・台湾の在庫調整やカナダ代理店変更でその他地域が減少。利益面では製品構成の変化等による売上原価率の上昇、学会等の出展費用・認証に伴う支払報酬の増加、上場関連費用の計上が影響。
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年4月1日〜2025年6月30日 |
| Net Sales | ¥2,434 million (YoY +3.6%) |
| Operating profit | ¥1,195 million (YoY -4.2%) |
| Ordinary income | ¥1,125 million (YoY -11.1%) |
| Profit attributable to owners of the parent | ¥745 million (YoY -9.3%) |
| Net income per share | 18.64円 |
| Equity ratio | End of the current fiscal period 94 / End of previous period 92.4 |
| Total assets | ¥18,471 million |
| Net assets | ¥17,355 million |
| Full-year earnings forecast | Net Sales ¥10,602 million (YoY +2.9%) / Operating profit ¥5,374 million (YoY -7.1%) / Ordinary income ¥5,267 million (YoY -8.7%) / Net income ¥3,498 million (YoY -7.7%) |
| Annual Dividend Forecast | ¥41 → ¥41(0.0%) |
| Regional sales | ¥895 million (YoY +103.6%), ¥1,538 million (YoY +103.6%), ¥844 million (YoY +109.7%), ¥242 million (YoY +106.0%), ¥133 million (YoY +107.7%), ¥145 million (YoY +218.5%), ¥173 million (YoY +58.5%) |
| Depreciation and amortization | ¥43 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on Sale of Fixed Assets ¥0 million / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No (no target participants specified) |
| Issued Shares at Period-End | 40,000,000 Shares |
| Treasury Shares at Period-End | 0 Shares |
| Factors Behind Changes in Business Performance | 国内では採卵針・カテーテルの新製品・改良品の販売が好調。海外では欧州の新製品展開・新規顧客開拓、インドの顧客開拓が進展した一方、タイ・台湾の在庫調整やカナダ代理店変更でその他地域が減少。利益面では製品構成の変化等による売上原価率の上昇、学会等の出展費用・認証に伴う支払報酬の増加、上場関連費用の計上が影響。 |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.売上高は、国内で採卵針・カテーテルの新製品・改良品の販売が好調だったこと、海外で欧州の新製品展開や新規顧客開拓、インドでの顧客開拓が進んだことが増収要因となった。一方、タイ・台湾での在庫調整やカナダ代理店変更によりその他地域の売上が減少した。営業利益は学会等の出展費用や認証に伴う支払報酬の増加、経常利益は上場関連費用の計上が減益要因となった。